Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Next Previous
Search
Trial Profile

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Gemcitabine (Primary) ; Pegargiminase (Primary)
  • Indications Non-small cell lung cancer; Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 04 Jun 2024 Trial design from this study assessing the safety, tolerability, to determine the recommended phase II dose (R2PD) and evaluate the efficacy of this combination in patients with previously treated metastatic non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) with an alternative dosing regimen than that used in STS based on the mechanism of action were presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 24 May 2024 Planned End Date changed from 30 Jun 2032 to 31 Dec 2032.
    • 24 May 2024 Planned primary completion date changed from 30 Jun 2027 to 31 Dec 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top